It has that divot that you saw that you can snap — that you can snap those together. So, yes, the development process, we’ve got multiple world-class partners that are working with us on this that have extensive experience in developing similar devices, whether it be the circuitry, the battery, optimizing software within the device, having the Bluetooth connectivity so that how the data that’s collected is transmitted by bluetooth to the patient’s phone and ultimately all of that is being handled by, in partnership with firms that have extensive experience in this. And as I said, it’s going extremely well. The FDA has very high standards with regard to how this data gets collected, how it gets transmitted. So many of those standards are built into the FDA process.
As I said, we’ve had numerous interactions with FDA. We’re down to our last couple of pre-submission meetings on a couple of the final features that will get us towards the — path towards putting together a 510k package and submitting it. The issues that you raise are important and front and center in these kinds of devices these days around cybersecurity and privacy and so forth. All of those are just — all of those considerations are just deeply built into the design process from day one. So we’re not breaking new ground here. We’re just taking established best practices and compliance. We have a very robust compliance infrastructure both internally as well as we have dedicated cybersecurity — a dedicated cybersecurity consultant that frankly works across all of our companies on all of our cybersecurity matters, but obviously is intimately involved in this process as well.
So we’re very aware of those considerations and all that work is being done with a very robust theme and with really careful attention to the requirements as well as best practice.
Anthony Vendetti: Excellent. That’s a great color. And then maybe switching just briefly to Lucid, I know you did the call yesterday. You have a new revenue cycle management firm that seems to be producing the results that you’re looking for. I guess on the call, Dennis you mentioned that based on the trends and where you’re at, fourth quarter could be on track for $1 million or a little bit north of $1 million. It was that accurate? I didn’t know if I heard that correctly, but maybe just summarize that a little bit for me. Thanks.
Dennis McGrath: Yes, that’s correct. For the first six weeks of the quarter, the average weekly collections are about 33% higher than the average for the entire prior quarter. So just doing the simple math, you’re correct. It’s trending to over $1 million in collections for the fourth quarter.
Anthony Vendetti: Okay, excellent. Thanks very much. I appreciate it. I’ll hop back into the queue.
Lishan Aklog: Thanks, Anthony.
Operator: Ladies and gentlemen, this concludes our question-and-answer session. I would like to now turn the conference back over to management for any closing remarks.
Lishan Aklog: All right, great. Hey, thank you everyone for your time. Thank you for the excellent questions. Really excited about this past quarter for PAVmed and its subsidiaries, particularly the strong quarter that Lucid Added. We look forward to continuing on that progress. As always, feel free to — we’ll continue to update you through quarterly calls and press releases, but in the interim, feel free to contact us with any questions. You can contact Mike Park at mep@pavmed.com. So thank you for your time and attention, and have a great day.
Operator: This concludes today’s conference call. We thank you all for attending today’s presentation. You may now disconnect your lines, and have a wonderful day.